{'52WeekChange': -0.07124996,
 'SandP52WeekChange': None,
 'address1': 'RMPE building',
 'address2': '12 Hartom Street Har Hotzvim PO Box 45219',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 0.4413,
 'askSize': 900,
 'averageDailyVolume10Day': 23999962,
 'averageVolume': 10961990,
 'averageVolume10days': 23999962,
 'beta': 0.737201,
 'beta3Year': None,
 'bid': 0.4305,
 'bidSize': 1800,
 'bookValue': 0.268,
 'category': None,
 'circulatingSupply': None,
 'city': 'Jerusalem',
 'companyOfficers': [],
 'country': 'Israel',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 0.497,
 'dayLow': 0.43,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.827,
 'enterpriseToRevenue': None,
 'enterpriseValue': 21095236,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 0.34597144,
 'fiftyTwoWeekHigh': 1.56,
 'fiftyTwoWeekLow': 0.132,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 56399459,
 'forwardEps': -0.12,
 'forwardPE': -3.7075002,
 'fromCurrency': None,
 'fullTimeEmployees': 38,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.1019,
 'heldPercentInstitutions': 0.17016001,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/intecpharma.com',
 'longBusinessSummary': 'Intec Pharma Ltd., a clinical stage biopharmaceutical '
                        'company, focuses on developing drugs based on its '
                        'proprietary Accordion Pill platform technology in '
                        'Israel. Its Accordion Pill is an oral drug delivery '
                        'system that is designed to enhance the efficacy and '
                        'safety of existing drugs and drugs in development by '
                        'utilizing a gastric retention and specific release '
                        "mechanism. The company's lead product candidate is "
                        'Accordion Pill Carbidopa/Levodopa, which is in a '
                        'Phase III clinical trial for the treatment of '
                        "Parkinson's disease symptoms in advanced Parkinson's "
                        'disease patients. It is also developing Accordion '
                        'Pill Zaleplon that is in a Phase III clinical trial '
                        'as a treatment for the induction and maintenance of '
                        'sleep in patients suffering from insomnia; a product '
                        'candidate, which has completed a Phase I clinical '
                        'trial for the prevention and treatment of '
                        'gastroduodenal and small bowel Nonsteroidal '
                        'Anti-Inflammatory Drug induced ulcers; and '
                        'AP-CBD/THC, AP-THC, and AP-CBD product candidates '
                        'with Cannabidiol and 9-Tetrahydrocannabinol for the '
                        'treatment of various indications, including low back '
                        'pain, neuropathic pain, and fibromyalgia. Intec '
                        'Pharma Ltd. has a research collaboration agreement '
                        'with Merck to explore using the Accordion Pill '
                        'platform for development program. The company was '
                        'formerly known as Intec Pharmaceuticals (2000) Ltd. '
                        'and changed its name to Intec Pharma Ltd. in March '
                        '2004. Intec Pharma Ltd. was founded in 2000 and is '
                        'based in Jerusalem, Israel.',
 'longName': 'Intec Pharma Ltd.',
 'market': 'us_market',
 'marketCap': 30816224,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_2241741',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -40813000,
 'nextFiscalYearEnd': 1640908800,
 'open': 0.44,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '972 2 586 4657',
 'previousClose': 0.4458,
 'priceHint': 4,
 'priceToBook': 1.6600746,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 0.497,
 'regularMarketDayLow': 0.43,
 'regularMarketOpen': 0.44,
 'regularMarketPreviousClose': 0.4458,
 'regularMarketPrice': 0.44,
 'regularMarketVolume': 12198316,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 69265504,
 'sharesPercentSharesOut': 0.0334,
 'sharesShort': 2313907,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1055242,
 'shortName': 'Intec Pharma Ltd.',
 'shortPercentOfFloat': 0.0336,
 'shortRatio': 0.24,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'NTEC',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.097,
 'twoHundredDayAverage': 0.307259,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '86b73588-aa1a-3c95-9952-be69268361b8',
 'volume': 12198316,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.intecpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '9777512'}